CSF3 and myalgic encephalomeyelitis/chronic fatigue syndrome: The most relevant side effects described were (1) anaemia, with around 54% of treated patients reported a reduction in haemoglobin of ≥3 g/dL; (2) neutropenia and thrombocytopenia, leading to compensatory drugs such as granulocyte colony-stimulating factor (G-CSF) and thrombopoietin receptor agonists (eltrombopag) being used in these patients [69,70,71,72]; and (3) chronic fatigue syndrome and psychiatric symptoms such as depression [69,70,71,72].